Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis
Objective. To investigate the differences of candidate cerebrospinal fluid (CSF) biomarkers associated with multiple system atrophy (MSA) and Parkinson’s disease (PD). Method. Here, a systematic review and meta-analysis were conducted on studies related to CSF biomarkers associated with MSA and PD o...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Behavioural Neurology |
| Online Access: | http://dx.doi.org/10.1155/2021/5559383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564510116806656 |
|---|---|
| author | Dan Xie Ling Feng Hongyan Huang Quanzhen Zhao Pingping Ning Qiuyan Shen Haitao Lu Fang Xu Yanming Xu |
| author_facet | Dan Xie Ling Feng Hongyan Huang Quanzhen Zhao Pingping Ning Qiuyan Shen Haitao Lu Fang Xu Yanming Xu |
| author_sort | Dan Xie |
| collection | DOAJ |
| description | Objective. To investigate the differences of candidate cerebrospinal fluid (CSF) biomarkers associated with multiple system atrophy (MSA) and Parkinson’s disease (PD). Method. Here, a systematic review and meta-analysis were conducted on studies related to CSF biomarkers associated with MSA and PD obtained from PubMed, Web of Science, Embase, and Cochrane databases. Data were pooled where appropriate and used to calculate standardized mean differences (SMDs) with 95% confidence intervals (CI). Heterogeneity was assessed using the I2 statistic while Egger’s test was used to test for existing publication bias. Results. MSA patients had higher CSF t-tau (SMD=0.41, 95% CI: 0.10 to 0.72) and YKL-40 (SMD=0.63, 95% CI 0.12 to1.15) as well as DJ-1 (SMD=1.05, 95% CI 0.67 to 1.42) levels than PD patients, while CSF p-tau (SMD=−0.17, 95% CI, -0.31 to -0.02) and Aβ-42 (SMD=−0.33, 95% CI, -0.55 to -0.12) levels in MSA patients were lower than those in PD patients. There were no differences in CSF’s GFAP and Flt3 ligand levels in both MSA and PD patients. Conclusion. The study revealed the differences in CSF biomarker levels between MSA and PD cohorts that can be further explored to clinically distinguish MSA from PD. |
| format | Article |
| id | doaj-art-e7ff31ec61fa4b59a86e3a0dec371ee8 |
| institution | Kabale University |
| issn | 0953-4180 1875-8584 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Behavioural Neurology |
| spelling | doaj-art-e7ff31ec61fa4b59a86e3a0dec371ee82025-02-03T01:10:54ZengWileyBehavioural Neurology0953-41801875-85842021-01-01202110.1155/2021/55593835559383Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-AnalysisDan Xie0Ling Feng1Hongyan Huang2Quanzhen Zhao3Pingping Ning4Qiuyan Shen5Haitao Lu6Fang Xu7Yanming Xu8Department of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaDepartment of Neurology, Sichuan University West China Hospital, Chengdu, 610041 Sichuan, ChinaObjective. To investigate the differences of candidate cerebrospinal fluid (CSF) biomarkers associated with multiple system atrophy (MSA) and Parkinson’s disease (PD). Method. Here, a systematic review and meta-analysis were conducted on studies related to CSF biomarkers associated with MSA and PD obtained from PubMed, Web of Science, Embase, and Cochrane databases. Data were pooled where appropriate and used to calculate standardized mean differences (SMDs) with 95% confidence intervals (CI). Heterogeneity was assessed using the I2 statistic while Egger’s test was used to test for existing publication bias. Results. MSA patients had higher CSF t-tau (SMD=0.41, 95% CI: 0.10 to 0.72) and YKL-40 (SMD=0.63, 95% CI 0.12 to1.15) as well as DJ-1 (SMD=1.05, 95% CI 0.67 to 1.42) levels than PD patients, while CSF p-tau (SMD=−0.17, 95% CI, -0.31 to -0.02) and Aβ-42 (SMD=−0.33, 95% CI, -0.55 to -0.12) levels in MSA patients were lower than those in PD patients. There were no differences in CSF’s GFAP and Flt3 ligand levels in both MSA and PD patients. Conclusion. The study revealed the differences in CSF biomarker levels between MSA and PD cohorts that can be further explored to clinically distinguish MSA from PD.http://dx.doi.org/10.1155/2021/5559383 |
| spellingShingle | Dan Xie Ling Feng Hongyan Huang Quanzhen Zhao Pingping Ning Qiuyan Shen Haitao Lu Fang Xu Yanming Xu Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis Behavioural Neurology |
| title | Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis |
| title_full | Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis |
| title_fullStr | Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis |
| title_full_unstemmed | Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis |
| title_short | Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis |
| title_sort | cerebrospinal fluid biomarkers in multiple system atrophy relative to parkinson s disease a meta analysis |
| url | http://dx.doi.org/10.1155/2021/5559383 |
| work_keys_str_mv | AT danxie cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT lingfeng cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT hongyanhuang cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT quanzhenzhao cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT pingpingning cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT qiuyanshen cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT haitaolu cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT fangxu cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis AT yanmingxu cerebrospinalfluidbiomarkersinmultiplesystematrophyrelativetoparkinsonsdiseaseametaanalysis |